Roche Holding AG
SIX:ROG
Intrinsic Value
Roche Holding AG operates as a research healthcare company. [ Read More ]
The intrinsic value of one
ROG
stock under the Base Case scenario is
295.2
CHF.
Compared to the current market price of 288.8 CHF,
Roche Holding AG
is
Undervalued by 2%.
Fundamental Analysis
Balance Sheet Decomposition
Roche Holding AG
| Current Assets | 33.8B |
| Cash & Short-Term Investments | 9.8B |
| Receivables | 11.9B |
| Other Current Assets | 12.1B |
| Non-Current Assets | 54.3B |
| PP&E | 24.2B |
| Intangibles | 20.5B |
| Other Non-Current Assets | 9.6B |
| Current Liabilities | 27.2B |
| Accounts Payable | 4.6B |
| Short-Term Debt | 2.2B |
| Other Current Liabilities | 20.5B |
| Non-Current Liabilities | 32.9B |
| Long-Term Debt | 21.4B |
| Other Non-Current Liabilities | 11.5B |
ROG Profitability Score
Profitability Due Diligence
Roche Holding AG's profitability score is 73/100. The higher the profitability score, the more profitable the company is.
Score
Roche Holding AG's profitability score is 73/100. The higher the profitability score, the more profitable the company is.
ROG Solvency Score
Solvency Due Diligence
Roche Holding AG's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
Roche Holding AG's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ROG Price Targets Summary
Roche Holding AG
According to Wall Street analysts, the average 1-year price target for
ROG
is 319.15 CHF
with a low forecast of 252.5 CHF and a high forecast of 399 CHF.
Shareholder Return
ROG Return Decomposition
Main factors of price return
Market capitalization of
ROG
shares
increased
by
49.57%
over the past 5 years.
The primary factor behind the change was
an increase
in P/E multiple from
14.7
to
18.6, leading to a
growth
in the market capitalization of Roche Holding AG by 28.47%.
Market capitalization of
ROG
shares
increased
by
49.57%
over the past 5 years.
The primary factor behind the change was
an increase
in P/E multiple from
14.7
to
18.6, leading to a
growth
in the market capitalization of Roche Holding AG by 28.47%.
ROG Price
Roche Holding AG
| Average Annual Return | 19.03% |
| Standard Deviation of Annual Returns | 13.08% |
| Max Drawdown | -34% |
| Market Capitalization | 231B CHF |
| Shares Outstanding | 800 579 145 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Roche Holding AG
Country
Industry
Market Cap
Dividend Yield
Description
Roche Holding AG operates as a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 100,920 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Contact
IPO
Employees
Officers
The intrinsic value of one
ROG
stock under the Base Case scenario is
295.2
CHF.
Compared to the current market price of 288.8 CHF,
Roche Holding AG
is
Undervalued by 2%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
